Close

Pharm-Olam Wins 2019 CRO Leadership Awards

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Pharmacy’s Impact on Reducing Medication Errors in Hospital Settings

Medication errors are a big problem in healthcare because...

How to Dispose of Pharmaceutical Waste

Proper pharmaceutical waste disposal is crucial for protecting our...

Semaglutide 101: What You Need to Know About This Game-Changing Medication

In the realm of modern medicine, breakthroughs are not...

Health Benefits of Pre-work Supplements

Whether you are a workout expert or just starting...

Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, has been named a winner in Life Science Leader magazine’s 2019 CRO Leadership Awards.

Pharm-Olam was rated highly by small pharma survey respondents, as well as all survey respondents combined, for delivering excellent clinical research services in Compatibility, Quality, and Reliability core award categories.

“Our team works very hard to earn our reputation for quality performance and nimble, expert service,” said David L. Grange, CEO, Pharm-Olam. “Not only do we hold ourselves accountable for study conduct, but also for study site and vendor performance. Sponsors have come to rely on us for the extra attention to detail that leads to successful trials.”

Life Science Leader’s annual CRO Leadership Awards are based on actual customer feedback. They are intended to help clinical researchers decide which outsource partners to work with. “We share our clients’ commitment to creating a healthier world through research,” said Grange. “And as these awards show, customers appreciate our high standards, particularly in the context of challenging international trials.”

This year, the magazine again worked with Industry Standard Research to perform the CRO Quality Benchmarking Survey. Sixty CROs were assessed on more than 20 performance metrics. Survey participants were decision-makers recruited from pharma and biopharma companies of all sizes. Respondents only evaluated companies they’d worked on an outsourced project with in the past 18 months.

CROs may win these awards in up to three groups of outsourcing respondents — big pharma, small pharma, and overall (big and small pharma combined). Core award categories include Capabilities, Compatibility, Expertise, Phase IV, Quality, and Reliability.

 For more information on Pharm-Olam’s full-service global support for Phase I-IV clinical trials, visit Pharm-Olam.com

About Pharm-Olam
Pharm-Olam is Helping Create a Healthier World as a global, midsized CRO that offers flexible, innovative and highly personalized clinical solutions to pharmaceutical, biotechnology and life science companies. Our team is well-known for producing quality results with reduced risk, costs and timelines in challenging international trials. Learn more about our full-service solutions, data protection services and expertise in oncology, infectious diseases and vaccines, rare and orphan diseases, pediatrics and general medicine at pharm-olam.com.

Latest stories